Immune checkpoint inhibitors (ICIs) have significantly driven the oncology treatment landscape as they immensely shift better clinical outcomes among various type of cancers. Challenges of using this approach are, without doubt, the immune related adverse events (IrAEs). These can have vital impact to affect multiple organs and some cases lead to fatality. Therefore, risk stratification should be cautiously taken into consideration while clinicians are dealing with ICIs. In this article, the risk factors from clinical trials or real-world reports that relevant to onset, level of severity, and particular type of IrAEs were discussed in order to promote IrAEs prompt attention in clinical practice
Keywords
Immune checkpoint inhibitors; Immune related adverse events; cancer; immunotherapy